, /PRNewswire/ — USA News Group News Commentary – Artificial intelligence (AI) is revolutionizing healthcare, offering solutions that could dramatically reduce deficits in the U.S. healthcare system. The U.S. Food and Drug Administration (FDA) is already shifting its focus toward the possibilities of Generative AI (GenAI), having recently presented a detailed 30-page report to its committee members outlining the technology’s potential. Capable of processing and synthesizing vast amounts of data with unparalleled speed, GenAI is emerging as a transformative force in healthcare innovation. From accelerating drug discovery to refining diagnostics and monitoring treatments, AI advancements are driving rapid progress, fueled by the efforts of companies like Avant Technologies, Inc. (OTCQB: AVAI), Roche Holding AG (OTCQX: RHHBY, RHHVF), Amazon.com, Inc. (NASDAQ: AMZN), Spectral AI, Inc. (NASDAQ: MDAI), Medtronic plc (NYSE: MDT), and GE HealthCare Technologies Inc. (NASDAQ: GEHC).
The article continued: Driving this AI transformation is a booming $9.58 billion market for AI Training …